Astellas Pharma reported a sharp rise in first-quarter profit attributable to owners of the parent, which climbed to 141.81 billion yen from 68.42 billion yen a year earlier. Revenue increased to 640.91 billion yen from 505.79 billion yen, while operating profit jumped to 184.51 billion yen from 94.65 billion yen. Earnings per share were 78.96 yen versus 38.11 yen last year. For fiscal 2027, the company expects revenue to grow 3.8% year over year to 2.22 trillion yen, operating profit to rise 3.2% to 395 billion yen, and profit attributable to owners of the parent to increase 2.9% to 300 billion yen, with basic earnings per share projected at 167.46 yen.
Astellas Pharma Inc.Q1 profit and revenue surged, with raised FY27 guidance.
